ResMed Inc. vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? ResMed Inc. trades at $238.48 (market cap $32.99B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $286.02 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.13%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| RMD | WAB | |
|---|---|---|
Market Cap | $32.99B | $48.39B |
Volume | 1,023,381 | 801,560 |
Sector | Health | Industrials |
52-Week High | $275.96 | $305.79 |
52-Week Low | $182.82 | $193.43 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.35B | $54.29B |
Dividend Yield | 1.13% | 0.43% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →